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Background:  The use of packed red blood cell (PRBC) transfusion has been associated with higher rates of morbidity and mortality in patient 
populations such as the critically ill and those who have had acute coronary syndromes, cardiac surgery, and surgical revascularization for peripheral 
arterial disease (PAD). The reason for this is not fully understood. We hypothesized that PRBC transfusion following endovascular therapy of PAD 
would be associated with similarly poor outcomes.
Methods:  De-identified public discharge data were obtained from the California Office of Statewide Health Planning and Development. Inpatient 
admissions that involved endovascular treatment of PAD between 1999 and 2006 were selected using ICD-9 procedure codes for retrospective 
review. Admitting diagnoses, baseline patient characteristics, and the use of PRBC transfusion were obtained. The primary outcome was in-hospital 
mortality. The secondary outcome was in-hospital myocardial infarction (MI). Categorical variables were compared using Fisher’s Exact test and 
continuous variables were compared using paired t-test. A generalized linear model was used to determine significance in a multivariable regression.
Results:  Between 1999 and 2006, there were 77,484 admissions during which an endovascular procedure for PAD was performed. Of those, 
10,204 (13.2%) patients received a PRBC transfusion. Patients requiring transfusion had more frequent histories of hypertension, diabetes, 
dyslipidemia, congestive heart failure, anemia, renal disease, and tobacco use. After adjusting for these comorbidities, transfused patients still had 
significantly higher in-hospital mortality (8.9% vs. 2.5%; OR 2.8 [95% CI 2.4-3.2]; p<0.001) and MI (7.7% vs. 2.7%; OR 1.99 [1.7-2.3] ; p<0.001.
Conclusion: PRBC transfusion is associated with higher rates of in hospital mortality and myocardial infarction in patients undergoing 
endovascular therapy of PAD even after adjustment for baseline differences in the respective patient populations. Further study is warranted to 
explore the mechanism of these findings.
